A rise in adverse clinical events with NOAC-regime after TAVR resulted in termination of trial

Media formats available:

Possible favorable effects of icosapent ethyl on plaque-parameters
Possible favorable effects of icosapent ethyl on plaque-parameters
AHA 2019
Possible favorable effects of icosapent ethyl on plaque-parameters
- Prof. Stephen Nicholls
Improved health status with SGLT2-inhibitor in HFrEF
Improved health status with SGLT2-inhibitor in HFrEF
AHA 2019
Improved health status with SGLT2-inhibitor in HFrEF
- Prof. Mikhail Kosiborod
Fish oil treatment reduces several plaque parameters after 9 months
Fish oil treatment reduces several plaque parameters after 9 months
AHA 2019
Fish oil treatment reduces several plaque parameters after 9 months
- Prof. Lawrence Leiter, MD
Is HF the same disease across the EF spectrum, or does HF have two physiologies that respond differently to treatment?
Is HF the same disease across the EF spectrum, or does HF have two physiologies that respond differently to treatment?
AHA 2019
Is HF the same disease across the EF spectrum, or does HF have two physiologies that respond differently to treatment?
- Prof. Lynne Stevenson

PACE-CME